Biotech Values

[DewDiligence]

Clarification on HBV combo therapy:

In #msg-18783113 I said: “The fact that prior Lamivudine treatment raises resistance to Baraclude is one of the reasons that dual nucleoside treatment for HBV has not been considered a good idea.”

This applies to dual nucleoside therapy as opposed to nucleoside + nucleotide combination therapy, which is considered a promising approach, albeit one that has yet to bear fruit.